vs
DigitalBridge Group, Inc.（DBRG）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
再鼎医药的季度营收约是DigitalBridge Group, Inc.的1.2倍（$127.1M vs $105.7M），再鼎医药同比增速更快（17.1% vs 4.1%），DigitalBridge Group, Inc.自由现金流更多（$258.0M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs 19.2%）
DigitalBridge Group（DBRG）是全球领先的数字基础设施投资企业，核心业务覆盖通信基站、数据中心、光纤网络、小基站及边缘算力设施的投资、持有与运营。公司总部位于美国博卡拉顿，在洛杉矶、纽约、丹佛、伦敦、新加坡多地设有办公点，截至2025年6月，旗下管理资产规模达1060亿美元。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
DBRG vs ZLAB — 直观对比
营收规模更大
ZLAB
是对方的1.2倍
$105.7M
营收增速更快
ZLAB
高出13.0%
4.1%
自由现金流更多
DBRG
多$284.7M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
19.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $105.7M | $127.1M |
| 净利润 | $65.1M | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | — | -54.6% |
| 净利率 | 61.5% | — |
| 营收同比 | 4.1% | 17.1% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $0.28 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DBRGZLAB
| Q4 25 | $105.7M | $127.1M | ||
| Q3 25 | $93.3M | $115.4M | ||
| Q2 25 | $85.3M | $109.1M | ||
| Q1 25 | $90.1M | $105.7M | ||
| Q4 24 | $101.6M | $108.5M | ||
| Q3 24 | $76.6M | $101.8M | ||
| Q2 24 | $390.3M | $100.1M | ||
| Q1 24 | $74.4M | $87.1M |
净利润DBRGZLAB
| Q4 25 | $65.1M | — | ||
| Q3 25 | $31.4M | $-36.0M | ||
| Q2 25 | $31.6M | $-40.7M | ||
| Q1 25 | $13.8M | $-48.4M | ||
| Q4 24 | — | — | ||
| Q3 24 | $13.8M | $-41.7M | ||
| Q2 24 | $91.4M | $-80.3M | ||
| Q1 24 | $-29.6M | $-53.5M |
毛利率DBRGZLAB
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% | ||
| Q1 24 | — | 61.4% |
营业利润率DBRGZLAB
| Q4 25 | — | -54.6% | ||
| Q3 25 | -13.9% | -42.3% | ||
| Q2 25 | -31.2% | -50.3% | ||
| Q1 25 | -11.5% | -53.3% | ||
| Q4 24 | 5.7% | -62.6% | ||
| Q3 24 | 62.4% | -66.6% | ||
| Q2 24 | 33.5% | -76.0% | ||
| Q1 24 | -20.7% | -80.7% |
净利率DBRGZLAB
| Q4 25 | 61.5% | — | ||
| Q3 25 | 33.7% | -31.2% | ||
| Q2 25 | 37.1% | -37.3% | ||
| Q1 25 | 15.3% | -45.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | 18.0% | -40.9% | ||
| Q2 24 | 23.4% | -80.2% | ||
| Q1 24 | -39.8% | -61.4% |
每股收益（稀释后）DBRGZLAB
| Q4 25 | $0.28 | $-0.05 | ||
| Q3 25 | $0.09 | $-0.03 | ||
| Q2 25 | $0.10 | $-0.04 | ||
| Q1 25 | $-0.01 | $-0.04 | ||
| Q4 24 | — | $-0.09 | ||
| Q3 24 | $-0.01 | $-0.04 | ||
| Q2 24 | $0.44 | $-0.08 | ||
| Q1 24 | $-0.28 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $382.5M | $689.6M |
| 总债务越低越好 | $298.8M | — |
| 股东权益账面价值 | $2.1B | $715.5M |
| 总资产 | $3.4B | $1.2B |
| 负债/权益比越低杠杆越低 | 0.14× | — |
8季度趋势，按日历期对齐
现金及短期投资DBRGZLAB
| Q4 25 | $382.5M | $689.6M | ||
| Q3 25 | $358.4M | $717.2M | ||
| Q2 25 | $340.7M | $732.2M | ||
| Q1 25 | $349.9M | $757.3M | ||
| Q4 24 | $302.2M | $779.7M | ||
| Q3 24 | $294.4M | $616.1M | ||
| Q2 24 | $261.2M | $630.0M | ||
| Q1 24 | $247.4M | $650.8M |
总债务DBRGZLAB
| Q4 25 | $298.8M | — | ||
| Q3 25 | $327.9M | — | ||
| Q2 25 | $298.0M | — | ||
| Q1 25 | $296.9M | — | ||
| Q4 24 | $296.4M | — | ||
| Q3 24 | $295.8M | — | ||
| Q2 24 | $295.3M | — | ||
| Q1 24 | $366.5M | — |
股东权益DBRGZLAB
| Q4 25 | $2.1B | $715.5M | ||
| Q3 25 | $2.1B | $759.9M | ||
| Q2 25 | $2.0B | $791.7M | ||
| Q1 25 | $2.0B | $810.8M | ||
| Q4 24 | $2.0B | $840.9M | ||
| Q3 24 | $2.0B | $667.7M | ||
| Q2 24 | $2.0B | $704.2M | ||
| Q1 24 | $1.8B | $762.2M |
总资产DBRGZLAB
| Q4 25 | $3.4B | $1.2B | ||
| Q3 25 | $3.5B | $1.2B | ||
| Q2 25 | $3.4B | $1.2B | ||
| Q1 25 | $3.4B | $1.2B | ||
| Q4 24 | $3.5B | $1.2B | ||
| Q3 24 | $3.5B | $985.3M | ||
| Q2 24 | $3.5B | $987.4M | ||
| Q1 24 | $3.5B | $988.4M |
负债/权益比DBRGZLAB
| Q4 25 | 0.14× | — | ||
| Q3 25 | 0.16× | — | ||
| Q2 25 | 0.15× | — | ||
| Q1 25 | 0.15× | — | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | 0.15× | — | ||
| Q2 24 | 0.15× | — | ||
| Q1 24 | 0.20× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $259.3M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $258.0M | $-26.7M |
| 自由现金流率自由现金流/营收 | 244.0% | -21.0% |
| 资本支出强度资本支出/营收 | 1.3% | 0.5% |
| 现金转化率经营现金流/净利润 | 3.99× | — |
| 过去12个月自由现金流最近4个季度 | $440.5M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流DBRGZLAB
| Q4 25 | $259.3M | $-26.0M | ||
| Q3 25 | $56.5M | $-32.0M | ||
| Q2 25 | $77.0M | $-31.0M | ||
| Q1 25 | $50.3M | $-61.7M | ||
| Q4 24 | $60.1M | $-55.8M | ||
| Q3 24 | $35.9M | $-26.8M | ||
| Q2 24 | $22.5M | $-42.2M | ||
| Q1 24 | $-27.0M | $-90.1M |
自由现金流DBRGZLAB
| Q4 25 | $258.0M | $-26.7M | ||
| Q3 25 | $56.1M | $-35.0M | ||
| Q2 25 | $76.4M | $-33.9M | ||
| Q1 25 | $50.0M | $-63.2M | ||
| Q4 24 | $56.5M | $-58.4M | ||
| Q3 24 | — | $-28.2M | ||
| Q2 24 | $22.3M | $-42.9M | ||
| Q1 24 | $-30.1M | $-91.1M |
自由现金流率DBRGZLAB
| Q4 25 | 244.0% | -21.0% | ||
| Q3 25 | 60.2% | -30.4% | ||
| Q2 25 | 89.5% | -31.1% | ||
| Q1 25 | 55.5% | -59.9% | ||
| Q4 24 | 55.7% | -53.8% | ||
| Q3 24 | — | -27.7% | ||
| Q2 24 | 5.7% | -42.9% | ||
| Q1 24 | -40.4% | -104.5% |
资本支出强度DBRGZLAB
| Q4 25 | 1.3% | 0.5% | ||
| Q3 25 | 0.4% | 2.6% | ||
| Q2 25 | 0.7% | 2.6% | ||
| Q1 25 | 0.3% | 1.5% | ||
| Q4 24 | 3.5% | 2.4% | ||
| Q3 24 | 0.0% | 1.3% | ||
| Q2 24 | 0.1% | 0.7% | ||
| Q1 24 | 4.1% | 1.1% |
现金转化率DBRGZLAB
| Q4 25 | 3.99× | — | ||
| Q3 25 | 1.80× | — | ||
| Q2 25 | 2.43× | — | ||
| Q1 25 | 3.65× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.61× | — | ||
| Q2 24 | 0.25× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DBRG
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
